AstraZeneca shifts cancer drug production from UK to Ireland
Pharmaceutical giant Merck to manufacture flagship cancer drug Lynparza at new €1 billion Irish facility, dealing significant blow to UK's life sciences sector and raising fresh post-Brexit trade concerns.